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ABSTRACT  15 
As high-level recombinant protein production (RPP) exerts a massive stress on the production host, 16 
an extensive literature on RPP optimisation focuses on separating the growth phase from RPP 17 
production once sufficient biomass has been obtained. The aim of the current investigation was to 18 
optimise benefits of the relatively neglected alternative strategy to achieve high level RPP during 19 
growth by minimizing stress on the host.  High yields of the biopharmaceutical recombinant human 20 
Tumour Necrosis Factor alpha (rhTNFα) were obtained by fed-batch fermentation relevant to 21 
industrial production based upon parameters that most severely affected RPP in preliminary 22 
laboratory scale batch cultures.  Decreasing the inducer concentration and growth temperature but 23 
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increasing the production period were far more effective for increasing RPP yields than changing the 24 
growth phase at which production was induced.  High yields of up to 5 g·L-1 of rhTNFα were obtained 25 
with minimal plasmid loss even in synthetic media that lack animal-derived components and are 26 
therefore fully compliant with regulatory requirements. Most of the product was soluble and 27 
biologically active.  In summary, stress minimisation was shown to be an effective way to optimise 28 
production of rhTNFα. Data generated in shake-flask experiments allowed design of intensified 29 
bioreactor cultures in which RPP and growth could be balanced, leading to higher yield of both 30 
rhTNFα and biomass than previous fermentations. Additional benefits of this approach include 31 
avoidance of lysis during harvesting and downstream processing and the ability to adjust the process 32 
to minimize the need for long periods of staff supervision.   33 
INTRODUCTION 34 
Recombinant proteins (RP) for use as human biopharmaceuticals represent a commercially 35 
important product group for the pharmaceutical industry, with 40 % of pharmaceutical sales 36 
accounted for by biopharmaceutical drugs.  Seven of the top-selling 10 drug products in 2013 were 37 
protein biologics [1]. Bacteria such as Escherichia coli are favoured as the production host when the 38 
product is relatively simple and does not require glycosylation or other extensive posttranslational 39 
modification for function. E. coli remains an important host for biopharmaceutical production due to 40 
its relative simplicity when compared to mammalian cell systems such as CHO, and its ease of use 41 
[2]. 42 
An extensive literature documents two major routes for RP production in E. coli: generation of RPs 43 
in insoluble inclusion bodies, which although easy to harvest need first to be denatured then refolded 44 
in vitro to a functional soluble form [3]; or generation of soluble functional RP in vivo [4]. Although 45 
there are industrial examples of both routes, the former pathway relies upon successful refolding 46 
following inclusion body denaturation, which for many RPs can be very inefficient, complex and 47 
costly. Therefore, production of soluble RP in E. coli remains an important objective of process 48 
development. 49 
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Industrially relevant fermentation processes are designed to generate large quantities of RP along 50 
with high biomass yields. These conflicting objectives result in severe physiological stress on the 51 
bacterial host due to competition between the two processes for metabolic resources such as amino 52 
acids and other metabolites, aminoacylated tRNAs, energy and reducing power. Many successful 53 
fermentations avoid this conflict by separating the growth and RP production phases, thereby 54 
minimizing the selection of unproductive, plasmid-free bacteria or selection of mutants defective in 55 
RP accumulation.  In the current study we have exploited a less studied approach involving 56 
concomitant growth and RP production under conditions that decrease the stress on the host 57 
bacteria [5,6,7].  Previous studies have shown that by growing bacteria at a lower temperature and 58 
inducing production at a lower level by use of weaker promoters or lower inducer concentrations, RP 59 
production can be more easily balanced with biomass accumulation, allowing higher biomass 60 
concentrations to be achieved.  As RP is generated more slowly, successful folding is enhanced, 61 
thus increasing soluble protein production.  However, only a very few of the previous studies using 62 
this approach have reported the effects of all of the key variables such as the effects of medium 63 
composition, temperature, inducer concentration, the structure of the recombinant plasmid and then 64 
reported process development into fed batch cultivation.  In many cases the target was green 65 
fluorescent protein rather than an industrially important product, and the medium components used 66 
would not meet current GMP (Good Manufacturing Practice) requirements. 67 
Human Tumour Necrosis factor (TNFα) is a cell signalling protein involved in systemic inflammation 68 
and its primary role is the regulation of immune cells. TNFα is first synthesised in humans as a 26 69 
kDa transmembrane precursor protein, which is processed into an active, soluble 17 kDa protein 70 
that associates into homotrimers [8].  Recombinant human TNFα (rhTNFα) is currently on the market 71 
under the international non-proprietary name tasonermin. It is expressed as the soluble 17 kDa 72 
monomer in E. coli. It was approved by the European Medicines Agency in 1999 for the treatment of 73 
soft-tissue sarcoma and commercially produced by Boehringer Ingelheim under the trade name of 74 
Beromun®. TNFα was selected as a model RP in this study due to its commercial relevance, because 75 
it has been used for other studies as a model protein for cytoplasmic RP production in E. coli [9] and 76 
since reference material can be commercially obtained. Our first aim was to define parameters that 77 
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are most significant for the production of soluble rhTNFα in E. coli shake-flask cultures. Data from 78 
these initial studies were used to direct development of high cell density fed-batch bioreactor cultures 79 
that lack components of animal origin. The results demonstrate that stress minimisation can be 80 
successfully applied to generate soluble rhTNFα production in an industrially relevant process. 81 
METHODS 82 
Bacterial strain and plasmids 83 
E. coli BL21-T7 (F- ompT lon hsdSB(rB
- mB
-) gal dcm araBAD::T7RNAP) sourced from Cobra 84 
Biologics (Keele, UK) was used for the production of rhTNFα. The gene coding for hTNFα was 85 
synthesised and cloned into the pLT72 vector (Cobra Biologics, Keele, UK), under the transcriptional 86 
control of the T7 promoter.  Addition of arabinose to E. coli BL21-T7 induces production of the T7 87 
RNA polymerase, inducing expression from pLT72. Additionally, three different vectors were 88 
generated containing: (i) the sequence encoding the hTNFα gene and the T7 terminator sequence 89 
downstream from the multiple cloning site (pLT72-T7t-TNFα); (ii) the T7 terminator sequence and 90 
the kanamycin gene in reverse orientation (pLT72-T7tKan-TNFα); and (iii) the T7 and T2 terminator 91 
sequences flanking the kanamycin resistance gene (pLT72-T7tKanT2t-TNFα). Plasmid vectors 92 
pLT72 and the pLT72-TNFα were kindly generated by Bruce Humphrey at Cobra Biologics.  93 
Shake-flask growth experiments 94 
In initial experiments, biomass and rhTNFα production in induced and non-induced conditions in 95 
shake-flasks were compared using two commonly used media; Luria Bertani broth (LB) and Terrific 96 
broth (TB). Luria Bertani (LB) agar contained 10 g·L-1 BBLTM phytone peptone (BD), 5 g·L-1 BactoTM 97 
yeast extract (BD), 5 g·L-1 NaCl and 15 g·L- extra-pure agar (Merck Millipore) in deionised water. 98 
Luria Bertani (LB) broth contained 10 g·L-1 BBLTM phytone peptone, 5 g·L-1 BactoTM yeast extract 99 
and 5 g·L-1 NaCl in deionised water. Terrific broth (Life technologies) contained 47 g·L-1 of premade 100 
terrific broth powder (equivalent to 11.8 g·L-1 SELECT peptone 140, 23.6 g·L-1 yeast extract, 9.4 g·L-101 
1 K2HPO4 and 2.2 g·L-1 KH2PO4) and 4 mL·L-1 of glycerol in deionised water. Starter cultures were 102 
grown overnight at 30 °C and 200 rpm from a single colony of bacteria in 10 mL of LB broth with 50 103 
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μg·mL-1 kanamycin in a 20 mL bottle. Cultures were grown in 50 mL of LB or TB supplemented with 104 
50 μg·mL-1 kanamycin in 250 mL baffled shake-flasks. Sufficient inoculum was added to achieve a 105 
starting OD600 of 0.1. Upon induction, casamino acids were added to cultures to a final concentration 106 
of 2 %, as it has been reported that the addition of casamino acids has a beneficial effect on rhTNFα 107 
production [10]. 108 
Fed-batch fermentation methods are described in Supplemental information. 109 
For harvest of cell pellets for purification of rhTNFα, the culture was centrifuged at 3,500 g at 4 °C 110 
for 30 min (Sorvall RC3B Plus, rotor Sorvall HLR6/H6000A/HBBC). Pellets were resuspended in 111 
phosphate buffered saline (PBS; Gibco, Life Technologies) and homogenised using a Dounce 112 
homogeniser. The homogenised cell paste was centrifuged at 7,500 g at 4 °C for 30 min (Sorvall 113 
RC53 Plus, rotor Sorvall SS-34). Cell paste was stored at -20 °C.  114 
Analysis techniques 115 
The optical density of cultures at 600 nm (OD600) was measured using an Amersham Pharmacia 116 
Ultrospec 1100 Pro UV/ Visible Spectrophotometer. Culture samples were also serially diluted in 117 
PBS and plated onto LB agar for determination of CFU. For plasmid retention analysis, LB agar 118 
plates were incubated at 37 °C overnight; colonies were transferred by replica plating to LB agar and 119 
LB agar supplemented with 50 mg·L-1 kanamycin and incubated overnight at 37 °C.  120 
Subcellular fractionation 121 
For separation of soluble and insoluble protein fractions, a volume of culture equivalent to 1 mL at 122 
an OD600 of 1 was centrifuged at 12,000 g for 10 min. Pellets were re-suspended in 250 µL of 50 mM 123 
Tris-HCI pH 8, 10 mM MgCl2 and 1 µL of benzonase nuclease (Merck Millipore) and incubated on 124 
ice. Lysozyme (3 µL of 10 mg·mL-1; Sigma-Aldrich) was added and samples incubated on ice for 30 125 
mins. Cells were lysed using freeze / thaw cycles; a minimum of 3 cycles of freeze (ethanol/dry ice 126 
bath) and thaw (37 °C) were carried out for each sample. Samples were centrifuged at 12000 g for 127 
30 min, to separate the soluble (supernatant) and insoluble (pellet) protein fractions. Pellets were re-128 
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suspended in 250 µL of 50 mM Tris-HCI pH 8, 10 mM MgCl2, constituting the insoluble protein 129 
fraction.  130 
SDS-PAGE 131 
SDS-PAGE and Western blotting were performed according to standard methods as detailed in the 132 
supplemental information.  133 
Purification of rhTNFα 134 
The purification of rhTNFα obtained from fermentation studies was carried out by Nicola Barison at 135 
Cobra Biologics. A proprietary purification protocol was used for the purification of rhTNFα and only 136 
a summary of the process will be described here. The cell paste obtained from fermentation studies 137 
was resuspended and cells were disrupted by the use of a high-pressure cell disruption system 138 
(Constant systems). The soluble protein fraction was obtained by centrifugation and clarified. 139 
rhTNFα was purified by a process comprising an ammonium sulphate precipitation and several 140 
chromatography steps including anion exchange and heparin affinity chromatography. The final 141 
product presented a purity greater than 95 %, as quantified by densitometry from SDS-PAGE gels 142 
(Supplemental Fig. S1).  143 
TNFα cytotoxicity assay 144 
The C3H mouse fibrosarcoma cell line L929, a cell line sensitive to the activity of TNFα, was used 145 
to evaluate the activity of rhTNFα produced by fed-batch fermentation [11]. L929 cells were grown 146 
in T225 flasks with Eagle’s minimum essential medium (EMEM) supplemented with 10 % (v/v) fetal 147 
bovine serum (FBS), 2 mM glutamine and 0.1 % NaHCO3. The cell culture was incubated at 37 °C 148 
and 5 % CO2 for three days. Once they reached confluency, cell cultures were passaged to a new 149 
T225 flask by removing the culture medium, washing the cells with PBS, trypsinisation to detach 150 
cells, resuspension in fresh EMEM and transfer to new T225 flasks with fresh EMEM.  151 
For the cytotoxic bioassay, 6×104 cells suspended in EMEM medium were added to each well of a 152 
96 well plate and incubated at 37 °C and 5 % CO2 for 18 hours. Once confluent, the medium was 153 
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exchanged for fresh EMEM medium containing 2 μg·mL-1 actinomycin D, a cell growth inhibitor 154 
preventing cell proliferation and sensitising the cells to the activity of rhTNFα, leading to apoptosis 155 
[11]. Different concentrations of rhTNFα reference material (Life Technologies), rhTNFα purified from 156 
cell paste generated in fermentation 1 or buffer were added to the plates and incubated for 12 - 18 157 
hours at 37 °C and 5 % CO2. After incubation, the culture medium was discarded and 200 μL staining 158 
solution (0.5 % (v/v) crystal violet in 20 % (v/v) methanol) was added to each well for 10 minutes. 159 
The staining solution was discarded by inversion of the plate, and excess staining solution removed 160 
by the addition of deionised water. The waste was removed and the L929 cells were solubilised by 161 
the addition of 100 μL of 1 % (w/v) sodium dodecyl sulphate solution. The plate was incubated for 1 162 
hour on a rotary shaker at 180 rpm. The OD580 of each well was measured using a FLUOstar Omega 163 
Microplate Reader (BMG LABTECH). The mean absorbance for each triplicate set of standards or 164 
samples assayed were calculated. Using the mean absorbance data, the percentage of cytotoxicity 165 
was calculated using equation 2:  166 
% cytotoxicity= [1 −
absorbance of sample
absorbance of zero TNFα control
 ] ×  100   (2)  167 
The concentration of purified rhTNFα giving rise to a cytotoxicity value of 50 % (LD50) was 168 
determined. A hTNFα standard curve was constructed by plotting the percentage cytotoxicity values 169 
for the hTNFα standards against their concentration using GraphPad Prism® software. The standard 170 
curve was used to calculate the specific activity of the purified rhTNFα. A concentration of 1 unit (U) 171 
of specific activity per mL is defined as that which gives rise to 50 % cytotoxicity in the bioassay (ie 172 
the LD50).  173 
RESULTS AND DISCUSSION 174 
Selection of culture medium for the production of rhTNFα 175 
Expression of rhTNFα was driven from an arabinose-induced T7 expression system, similar to the 176 
widely-used DE3 / pET system [12]. E. coli strain BL21-T7 was used as a host, carrying a 177 
chromosomal T7 RNA polymerase gene under the control of an arabinose-inducible promoter. The 178 
gene encoding rhTNFα was cloned into pLT72 under the control of a T7-dependent promoter. In 179 
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initial experiments, E. coli BL21-T7 transformed with either pLT72-TNFα or the empty vector (pLT72) 180 
were grown with aeration in Luria Bertani broth (LB) or Terrific Broth (TB).  At an OD600 of 1, half of 181 
the cultures were induced with a final concentration of 0.2 % (w/v) arabinose and casamino acids 182 
were added [10].  Biomass accumulation, culturability (colony forming units), plasmid retention and 183 
protein production were analysed (Figs. 1 & 2).  Growth of cultures transformed with either the control 184 
plasmid or the production plasmid stopped soon after induction.  This was expected because 185 
production of T7 RNA polymerase, even without production of an RP, induces stress responses in 186 
E. coli [13].  The final biomass concentration in non-induced cultures in LB was higher than in TB.  187 
For each medium, non-induced cultures containing the empty vector and the vector encoding 188 
rhTNFα grew similarly. However, for induced cultures, TB cultures grew faster and reached a higher 189 
OD600 than LB cultures. After either 2 h or 24 h post-induction, induced cultures expressing rhTNFα 190 
also had higher culturability in TB than in LB. 191 
SDS-PAGE analysis revealed that rhTNFα accumulated gradually after induction, reaching a 192 
maximum of 20 % of the total cell protein after 24 hours of growth for both TB and LB (Fig. 2). Very 193 
little rhTNFα was present in cells before induction or in non-induced cells after 24 hours growth, 194 
revealing that this expression system offers tight regulation of RPP. Bacterial pellets harvested after 195 
24 hours growth were also fractionated into soluble and insoluble fractions.  SDS-PAGE revealed 196 
that around 55 % of the rhTNFα was present in the soluble fraction for both media. As a result of its 197 
buffering capacity and the slight improvements noted in growth and culturability, TB was selected for 198 
use in further experiments. 199 
SDS-PAGE analysis identified an unexpected protein band (~31 kDa) in induced cultures of cells 200 
carrying both the empty vector and the vector encoding rhTNFα. The concentration of this unknown 201 
protein band accounted for up to 10 % of the total cell protein (in samples from induced cultures 202 
carrying the empty vector). It was hypothesised that this unknown protein could be the product of 203 
the kanamycin resistance gene, aminoglycoside 3' phosphotransferase (APH), which has a 204 
comparable molecular weight. The lack of terminator sequences downstream of the multiple cloning 205 
site on the backbone of vector pLT72 may have allowed read-through by the T7 RNA polymerase, 206 
leading to the overproduction of APH. 207 
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Effect of inducer concentration and induction point on rhTNFα production 208 
Addition of 0.2 % (w/v) arabinose as an inducer in the previous experiment resulted in stress as 209 
evidenced by growth arrest, a decrease in viability and plasmid loss (potentially due to a decrease 210 
in culturability of plasmid-containing, productive, bacteria), even in cultures containing the empty 211 
vector. The effect of different inducer concentrations (1 %, 0.2 %, 0.05 %, 0.02 % or 0.002 % 212 
arabinose, added at an OD600 of 1) was tested. Bacteria transformed with the empty vector (pLT72) 213 
or the vector coding for rhTNFα (pLT72-TNFα) under non-inducing conditions were used as controls 214 
(Fig. 3). 215 
Growth of cultures induced with 1 % to 0.02 % arabinose was arrested following arabinose addition 216 
and more than 80% of the bacteria were plasmid deficient after 24 h. The final biomass concentration 217 
after 24 h was inversely proportional to the inducer concentration used, but higher for induced 218 
cultures transformed with the recombinant plasmid than the non-induced cultures or cultures 219 
containing empty vector (Fig. 3a). In contrast, growth of cultures induced with 0.002 % arabinose 220 
was only slightly inhibited (Fig. 3a), and more than 80 % of these bacteria had retained the plasmid 221 
after 24 h (Fig. 3b).  222 
The concentration of rhTNFα in cells after 24 hours growth was similar in all cultures (Fig. 3c), 223 
independent of the arabinose concentration used, showing that the lowest concentration of 224 
arabinose, 0.002 %, was sufficient to fully induce the T7 expression system. In addition, the majority 225 
of the rhTNFα was found to be accumulated in the soluble protein fraction independently of the 226 
concentration of arabinose used to induce the cultures (data not shown). 227 
The effect of changing the point of induction in shake-flasks was evaluated by inducing RP by adding 228 
0.2% arabinose at an OD600 of 0.5, 2 or 3 (Supplemental Fig. S2). Unlike changing the inducer 229 
concentration, there were no large differences between cultures induced at different cell densities. 230 
Cultures induced at an OD600 of 0.5 grew more slowly after induction but reached higher cell densities 231 
than those cultures induced at an OD600 of 2 or 3 (Supplemental Fig. S2a). There were no significant 232 
differences in CFU or in rhTNFα productivity for cultures induced at an OD600 of 0.5, 2 or 3 and 233 
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plasmid loss was observed 24 hours post-inoculation for all the induced cultures as a result of the 234 
high concentration of arabinose used (Supplementary Fig. 2b and data not shown).   235 
Effect of temperature on rhTNFα productivity 236 
As well as lowering inducer concentration, stress minimisation can be achieved by decreasing the 237 
temperature of growth, thus slowing growth and protein production rates. This has been previously 238 
been shown to favour accumulation of recombinant proteins in a soluble form [6,14]. Cultures were 239 
grown as before in TB supplemented with casamino acids, but at temperatures of 37 °C, 30 °C, or 240 
25 °C. Expression of rhTNFα was induced by the addition of arabinose to a final concentration of 0.2 241 
% at OD600 = 1, cell samples were harvested 4 hours after induction, separated into soluble and 242 
insoluble fractions and analysed by SDS-PAGE (Fig. 4a). The proportion of rhTNFα in the soluble 243 
fraction increased as the growth temperature decreased. 244 
To investigate the interplay between inducer concentration and temperature of growth, further 245 
cultures were grown as before at 25 °C and at OD600 = 0.5 induced with concentrations of arabinose 246 
between 0.2 % and 0.001 %. Plasmids were retained for 24 h by uninduced cultures or cultures 247 
transformed with the empty vector (Fig. 4b). Although  >90 % of bacteria induced with 0.2 % 248 
arabinose had lost the plasmid within 24 h, plasmids had been retained by most of the bacteria at 249 
much higher induced concentrations at 25 °C than at 30 °C (Compare Figs. 3b and 4b). Production 250 
of rhTNFα production was fully induced with 0.005 % and 0.002 % arabinose, but was suboptimally 251 
induced at 0.001 % arabinose (Fig. 4c). 252 
Intensification of rhTNFα production in fed-batch fermentations 253 
The optimal conditions for the production of rhTNFα defined during shake-flask studies were 254 
transferred to 5 L fed-batch fermentations using medium A, a semi-defined culture medium 255 
formulation obtained from Cobra Biologics, supplemented with 2 % casamino acids. Production of 256 
rhTNFα was induced with arabinose to a final concentration of 0.005 % at an OD600 of 0.5 after 3 257 
hours of growth (Fig. 5). The culture grew after inoculation reaching a final OD600 of 90.8 after 48 258 
hours (Fig. 5a).  Although µ initially exceeded 0.4 during the initial batch phase of growth, it 259 
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decreased below 0.4 after 6 hours. The CFU dropped after 7 hours growth, and plasmid retention 260 
dropped below 90 % after 11 hours (Fig. 5b). After 48 hours, only 2 % of the bacteria had retained 261 
the plasmid.  Although rhTNFα had accumulated to 22 % of cellular protein after 26 h, it did not 262 
significantly increase after that point (Fig. 5c). The increase in biomass between 26 h and 48 h did 263 
not correlate with an increase in rhTNFα productivity, as expected since the plasmid retention of the 264 
culture was low and decreasing. Production of the 31 kDa APH protein had also accumulated by 9 265 
h post-induction. Analysis of soluble and insoluble cellular fractions revealed that the majority of 266 
rhTNFα was present in the soluble fraction (Fig. 5d). 267 
Taken together, these data revealed that the fermentation conditions as defined in shake-flask 268 
studies were a good starting point for fermentation development, as rhTNFα was generated in the 269 
soluble fraction in significant quantities and induction of rhTNFα production did not cause growth 270 
arrest or immediate decreases in CFU or plasmid retention. However, harvesting the culture after 30 271 
h when the percentage of cellular protein that was rhTNFα was the greatest (25 %) would not have 272 
resulted in high overall rhTNFα yield due to the low biomass (OD600 < 40). This indicates that 273 
allocation of resources to growth and RPP was unbalanced. In addition, production of APH from 274 
pLT72-TNFα could have increased the metabolic burden on the cells. 275 
Improvement of vector design for minimisation of APH synthesis 276 
Although high yields of rhTNFα were obtained in bacteria transformed with plasmid pLT72-TNFα, 277 
plasmid deficient bacteria were detected 24 h post-induction under all growth conditions tested.  278 
Attempts were therefore made to decrease the stress on the host further by decreasing expression 279 
of AHP, which was suspected to be the abundant 31 kDa protein detected by SDS PAGE.  Three 280 
modified plasmids were constructed (Fig. 6a), and plasmid retention and rhTNFα accumulation 281 
during growth in small scale batch cultures were compared with those of the original plasmid.  For 282 
these experiments, bacteria were grown at 30 °C in Terrific Broth and RP was induced with 0.02 % 283 
arabinose. These conditions were known from previous experiments to show high plasmid loss, so 284 
any improvement in plasmid retention would indicate reduced stress [6]. 285 
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In contrast to the 20 % plasmid retention by pLT72-TNFα transformant, 40 % of the bacteria 286 
transformed with plasmid pLT72-T7t-TNFα in which the T7 terminator was cloned downstream of 287 
the TNFα gene had retained the plasmid 24 h post-induction (Fig. 6b).  Similar results were obtained 288 
with plasmid pLT72-T7tKanT2t-TNFα with both the T7 and the T2 terminators after the TNFα gene 289 
and the kanamycin gene in reverse orientation.  However, plasmid retention was further improved 290 
(~80 %) in cultures carrying the vector with the T7 terminator sequence and the kanamycin 291 
resistance gene in the opposite orientation to the rhTNFα gene (pLT72-T7tKan-TNFα). SDS-PAGE 292 
analysis of whole cell proteins at different time points during growth revealed no significant 293 
differences between the four vectors in terms of production of rhTNFα (Fig. 6c).  The abundance of 294 
the 31 kDa protein was slightly lower with the vector containing the T7 terminator sequence (pLT72-295 
T7t-TNFα); and decreased further for vectors with the sequence coding for kanamycin resistance 296 
gene in reverse orientation (pLT72-T7tKan-TNFα and pLT72-T7tKanT2-TNFα). These data confirm 297 
the identity of the 31 kDa protein as APH. Plasmid retention data identified pLT72-T7tKan-TNFα as 298 
the optimal construct due to its low rate of plasmid loss, indicative of lowered stress. 299 
Improvement of fed-batch fermentation using the improved expression vector 300 
The fed-batch fermentation was repeated with pLT72-T7tKan-TNFα, containing the T7 terminator 301 
sequence and the gene coding for the kanamycin resistance gene in reverse orientation 302 
(Supplemental Fig. S3). As before, the culture grew continuously, reaching a final OD600 of 68 after 303 
48 h (Supplemental Fig. S3a), although the OD600 only increased slightly after 33 h. The specific 304 
growth rate during the batch phase was comparable to the previous fermentation. CFU values 305 
decreased slightly less following induction (Supplemental Fig. S3b) compared to the fermentation 306 
using pLT72-TNFα (Fig. 5a), whereas plasmid retention remained at close to 100 % throughout. 307 
The quantity of rhTNFα was comparable to the fermentation using pLT72-TNFα, with 25 % of cellular 308 
protein being rhTNFα after 27 h (Supplemental Fig. S3c). After 48 h, the majority (>80 %) of rhTNFα 309 
was in the soluble fraction. The use of the improved vector design helped to minimise plasmid loss 310 
during fermentation, avoiding the overgrowth of plasmid-free cells, and therefore, non-productive 311 
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cells at the last stages of the fermentation process. However, this did not significantly increase the 312 
quantity of rhTNFα generated. 313 
Removal of casamino acids from fed-batch growth medium 314 
Good Manufacturing Practices (cGMP) for pharmaceutical products recommend that animal-derived 315 
products should be excluded from bacterial culture medium to eliminate risks from zoonotic viruses 316 
and transmissible spongiform encephalopathies. To develop a GMP compliant fermentation process, 317 
casamino acids (a complex medium component derived from casein) were removed from medium A 318 
and replaced with 14 g·L-1 of ammonium sulphate and 0.3 g·L-1 of calcium chloride. Bacteria 319 
transformed with plasmid pLT72-T7tKan-TNFα were induced at an OD600 of 0.5 with 0.005 % 320 
arabinose and sampled for up to 32 h post-induction.  The biomass concentration increased steadily 321 
reaching a final OD600 of 72 (Supplemental Fig. S4a). However, no great increase of the cell biomass 322 
was observed after 32 h, and in contrast to previous fermentations the growth rate decreased 323 
immediately following rhTNFα induction, (Fig. 5 & Supplemental Fig. S3). There was no decrease in 324 
CFU following induction of RPP (Supplemental Fig. S4b), but in contrast to 100 % retention of the 325 
plasmid in the presence of casamino acids, plasmid-free bacteria started to overgrow the culture 326 
after 9 h growth (Supplemental Fig. S3). The concentration of rhTNFα increased after induction, 327 
reaching a maximum of 26 % of total cell protein after 24 h growth (Supplemental Fig. S4c).  The 328 
concentration of rhTNFα decreased after 24 h, presumably due to outgrowth of plasmid-free, non-329 
productive cells. The concentration of rhTNFα in the soluble fraction was lower than in previous 330 
fermentations, with only 50 % of the rhTNFα in the soluble fraction after 48 h. Thus removal of 331 
casamino acids was detrimental to the fermentation process. Ben-Bassat et al. [15] and Hoffmann 332 
et al. [11] reported that casamino acids increased recombinant protein yields and/or stability, 333 
presumably due to enhanced supply of amino acids allowing more rapid protein synthesis without 334 
the need for generation of amino acids de novo. Casamino acids contains more free amino acids 335 
and more peptide fragments of smaller molecular mass (<250 Da) than the yeast extract also present 336 
in the medium [16]. 337 
Fermentation with an alternative medium composition 338 
14 
 
The semi-defined medium C is fully GMP compliant and has been used successfully both by 339 
pharmaceutical companies and to produce model proteins in E. coli fed-batch fermentations [7,9,17]. 340 
This medium was therefore used in 5 L fed batch fermentations to generate rhTNFα from bacteria 341 
transformed with plasmid pLT72-T7tKan-TNFα. As before, the addition of the feed was started 10 342 
hours after inoculation and the specific growth rate (µ) during the fed batch phase was maintained 343 
at 0.1 h-1 by the use of an exponential feeding profile. The culture was induced at an OD600 of 0.5 by 344 
the addition of arabinose to a final concentration of 0.005 %.  The pH was maintained at 7.0 by the 345 
addition of 20 % NH4OH or 5 M HCl. 346 
Exponential growth in medium C was faster than in media A or B, peaking at µ = 0.815 h-1 (Fig. 7a). 347 
Unlike previous fermentations, the growth rate increased following induction of RPP, then decreased. 348 
CFU measurements consistently increased throughout the fermentation (Fig. 7b) and plasmid 349 
retention remained at around 100 % throughout. The concentration of rhTNFα increased gradually 350 
after induction, reaching a maximum of 30 % of the total cell protein between 24 and 30 h of growth 351 
(Fig. 7c). At the end of the fermentation, rhTNFα constituted 25 % of the total cell protein, being 352 
primarily accumulated in the soluble fraction, with less than 30 % of rhTNFα in the insoluble fraction. 353 
Overall, this fermentation process successfully generated a greater yield of rhTNFα than previous 354 
fermentations, the majority being accumulated in a soluble form, minimising plasmid loss and using 355 
a culture medium compliant with cGMP guidelines.  356 
Bioassay of rhTNFα activity 357 
The final goal of any fermentation process is the production of a soluble and active product, and 358 
protein solubility is often a good indication of activity. However, this statement is not always true, and 359 
recombinant proteins might accumulate in a soluble form but with an incorrect conformation, which 360 
limits or abolishes biological activity. Therefore, the activity of rhTNFα was measured using a 361 
bioassay [18]. rhTNFα was purified from the cell paste generated in fermentation 1 (Fig. 5; purified 362 
rhTNFα shown in Supplemental Fig. S1). The C3H mouse fibrosarcoma cell line L929, which is 363 
sensitive to hTNFα, was used to evaluate the activity of the purified rhTNFα. The basis of the 364 
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bioassay is that unlike dead cells killed by hTNFα, live L929 cells are stained by the dye crystal violet 365 
(CV).  366 
The activity of the purified rhTNFα was calculated as the percentage of cytotoxicity by comparing 367 
the amount of dye taken up by cells incubated with different quantities of rhTNFα. rhTNFα samples 368 
purified from fermentation 1 had a 50 % cytotoxicity (LD50) value at a concentration of 0.349 ± 0.035 369 
ng∙mL-1. This in within the concentration range of 0.05 to 20 ng·mL-1 in which for most in vitro 370 
applications hTNFα exerts its biological activity. Comparison with LD50 values for rhTNFα standards 371 
(Life Technologies) revealed that the specific activity of the purified rhTNFα was 2.8×106 U·mg-1. 372 
Overall, the result of the cytotoxicity assay showed that the optimization of the fermentation 373 
conditions have led to the successful production of soluble and active product and the rhTNFα 374 
produced during by fed-batch fermentation was active and stable.  375 
In summary, stress minimisation has been demonstrated to be an effective tool for the optimisation 376 
of the production of the human biopharmaceutical rhTNFα. Data generated in shake-flask 377 
experiments allowed design of intensified bioreactor cultures in which RPP and growth could be 378 
balanced, leading to high quantities of both rhTNFα and biomass. Balanced growth, allowing RP to 379 
accumulate along with biomass and thus maintaining cell health and viability, is important not only 380 
for biomass and RP accumulation during the fermentation, but also for harvest. Unhealthy or 381 
stressed bacteria are more difficult to harvest by centrifugation and subsequent downstream 382 
processing steps [5].This strategy also enables more flexible scheduling of fermentations. 383 
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FIGURE LEGENDS 441 
Figure 1. Selection of culture medium for the optimisation of the production of rhTNFα. E. coli 442 
BL21-T7 carrying the empty vector (pLT72) or the vector encoding rhTNFα (pLT72-TNFα) were 443 
grown at 30 °C in LB (a,c,e) or TB (b,d,f); half of cultures were induced with 0.2 % arabinose at an 444 
OD600 ≈ 1. Samples were taken at regular intervals and (a,b) OD600, (c,d) CFU and (e,f) plasmid 445 
retention determined. Data shown are single values for CFU and plasmid retention and mean values 446 
from replica flasks for OD600, error bars are ±1 SD. 447 
Figure 2. Accumulation of rhTNFα in cultures grown in LB or TB culture media. E. coli BL21-448 
T7 carrying the empty vector (pLT72) or the vector encoding rhTNFα (pLT72-TNFα) were grown in 449 
(a) LB or (b) TB at 30 °C; half of cultures were induced with 0.2 % arabinose at an OD600 ≈ 1 and 450 
samples were taken at regular intervals. Whole cell lysates were separated by SDS-PAGE and 451 
protein stained with colloidal blue. M, marker; BI, before induction. The quantity of rhTNFα is 452 
expressed as a percentage of whole cell protein at the bottom of the gel. Samples collected at 24 453 
hours were also fractionated to obtain soluble (24S) and insoluble (24I) cell fractions facilitated by 454 
the addition of lysozyme (shown on right). The ~31kDa protein presumed to be APH is shown on the 455 
right. 456 
Figure 3. Effect of the inducer concentration on the production of rhTNFα. (a) Growth of E. coli 457 
BL21-T7 carrying the empty vector (pLT72, non-induced) or pLT72-TNFα, incubated at 30 °C and 458 
induced with between 1 % and 0.002 % arabinose at OD600 ≈ 1. (b) Plasmid retention after 24 hours 459 
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of growth as in (a). (c) SDS-PAGE showing accumulation of rhTNFα from whole cell lysates obtained 460 
24 hours post-inoculation. Data shown are mean values from two replica flasks for OD600 and plasmid 461 
retention, error bars are ±1 standard deviation. 462 
Figure 4. Effect of the temperature and inducer concentration on the production of rhTNFα. 463 
(a) SDS-PAGE gel showing the accumulation of the rhTNFα in the soluble (Sol) and insoluble (Ins) 464 
fractions 4 hours after induction. Cultures were induced with 0.2 % arabinose and grown at 37 °C, 465 
30 °C or 25 °C; samples were fractionated and rhTNFα quantified by densitometry to give the 466 
percentage of rhTNFα in the soluble and insoluble fractions. (b) Plasmid retention of cultures carrying 467 
either the empty vector (pLT72) or pLT72-TNFα were grown at 25 °C under non-induced conditions 468 
or induced at OD600 ≈ 0.5 with 0.2 % to 0.001 % arabinose. Data shown are mean values from two 469 
replica flasks, error bars are ±1 standard deviation. (c) SDS-PAGE gel showing the accumulation of 470 
rhTNFα from whole cell lysates after 24 hours of growth as in (b). 471 
Figure 5. Production of rhTNFα by fed-batch fermentation. E. coli BL21-T7 pLT72-TNFα was 472 
grown at 25 °C in medium A and induced with 0.005 % arabinose at OD600 ≈ 0.5 (t = 3h; solid arrow). 473 
Feed was started at t = 10h (dashed arrow). (a) Growth as determined using OD600 and specific 474 
growth rate. (b) CFU and plasmid retention.  (c) SDS-PAGE analysis of whole cell lysates. The 3h 475 
sample is immediately before induction. rhTNFα and APH are indicated, along with densitometric 476 
analysis of the percentage of cellular protein that is rhTNFα. The “–ve” sample is E. coli BL21-T7 477 
pLT72 (empty vector) after 24 hours of growth (non-induced). (d) Samples were separated into 478 
soluble and insoluble fractions. rhTNFα and lysozyme are indicated.     479 
Figure 6. Optimisation of vector design to confirm the identity of the 31 kDa protein as APH 480 
and to minimise its production. (a) Schematic of the new vector designs. Arrows indicate genes, 481 
stem-loops terminators (T7t and T2t). (b) Plasmid retention after 24 hours growth of cultures carrying 482 
the empty vector (pLT72) or the 4 vectors as in (a) grown at 30 °C under non-inducer or induced 483 
(0.02 % arabinose at OD600 ≈ 0.5) conditions. Data shown are mean values from two replica flasks, 484 
error bars are ±1 standard deviation. (c) SDS-PAGE gel showing the accumulation of rhTNFα and 485 
APH in whole cell lysates after 4 h, 8 h, 10 h, 12 h and 24 h growth as in (b). 486 
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Figure 7. Production of rhTNFα using an alternative fed-batch medium composition. E. coli 487 
BL21-T7 pLT72-T7tKan-TNFα was grown at 25 °C in medium C and induced with 0.005 % arabinose 488 
at an OD600 ≈ 0.5 (t = 5h; solid arrow). Feeding was started at t = 10h (dashed arrow). (a) Growth as 489 
determined using OD600 and specific growth rate. (b) CFU and plasmid retention. (c) SDS-PAGE 490 
analysis of whole cell lysates. The 5h sample is immediately before induction. rhTNFα is indicated, 491 
along with densitometric analysis of the percentage of cellular protein that is rhTNFα. The “–ve” 492 
sample is E. coli BL21-T7 pLT72 (empty vector, non-induced) after 24 hours of growth. Samples 493 
obtained at t = 48h were also fractionated into soluble (Sol) and insoluble (Ins) fractions to determine 494 
the quantities of soluble and insoluble rhTNFα.  495 
  496 
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 574 
Supplemental Figure S1. Final material obtained after the purification process of rhTNFα. The 575 
rhTNFα accumulated mainly in the monomeric form. The presence of the rhTNFα dimer and trimer 576 
could also be detected by SDS-PAGE (left) and western blot (right). Bands corresponding to other 577 
contaminant proteins could also be observed (orange circles). The final product had a purity greater 578 
than 95 % as determined by densitometry. The western blot was developed using an anti-TNFα 579 
antibody which confirmed the identity of the monomer, dimer and trimer forms of the rhTNFα 580 
produced by fed-batch fermentation. 581 
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Supplemental Figure S2. The effect of the induction point on the production of rhTNFα.  (a) 595 
Growth of E. coli BL21-T7 carrying the empty vector (pLT72) or the vector coding for rhTNFα (pLT72-596 
TNFα) incubated at 30 °C; cultures were induced with 0.2 % arabinose at OD600 ≈ 0.5, 2 or 3. (b) 597 
SDS-PAGE showing accumulation of rhTNFα from whole cell lysates before induction (BI), 2 hours 598 
and 4 hours after induction. Data shown are mean values from two replica flasks for OD600, error 599 
bars are ±1 standard deviation. 600 
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Supplemental Figure S3. Production of rhTNFα by fed-batch fermentation using optimised 606 
expression vector pLT72-T7tKan-TNFα. E. coli BL21-T7 pLT72-T7tKan-TNFα was grown at 25 °C 607 
in medium A and induced with 0.005 % arabinose at an OD600 ≈ 0.5 (t = 5h; solid arrow). Feeding 608 
was started at t = 10h (dashed arrow). (a) Growth as determined using OD600 and specific growth 609 
rate. (b) CFU and plasmid retention. (c) SDS-PAGE analysis of whole cell lysates. The 5h sample is 610 
immediately before induction. rhTNFα is indicated, along with densitometric analysis of the 611 
percentage of cellular protein that is rhTNFα. The “–ve” sample is E. coli BL21-T7 pLT72 (empty 612 
vector, non-induced) after 24 hours of growth. Samples obtained at t = 48h were also fractionated 613 
into soluble (Sol) and insoluble (Ins) fractions to determine the quantities of soluble and insoluble 614 
rhTNFα. 615 
  616 
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SUPPLEMENTAL FIGURE S4 617 
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Supplemental Figure S4. Production of rhTNFα by fed-batch fermentation without the 622 
addition of casamino acids. E. coli BL21-T7 pLT72-T7tKan-TNFα was grown in medium 623 
B at 25 °C and induced with 0.005 % arabinose at an OD600 ≈ 0.5 (t = 3h; solid arrow). 624 
Feeding was started at t = 10h (dashed arrow). (a) Growth as determined using OD600 and 625 
specific growth rate. (b) CFU and plasmid retention. (c) SDS-PAGE analysis of whole cell 626 
lysates. The 3h sample is immediately before induction. rhTNFα is indicated, along with 627 
densitometric analysis of the percentage of cellular protein that is rhTNFα. The “–ve” sample 628 
is E. coli BL21-T7 pLT72 (empty vector, non-induced) after 24 hours of growth. Samples 629 
obtained at t = 48h were also fractionated into soluble (Sol) and insoluble (Ins) fractions to 630 
determine the quantities of soluble and insoluble rhTNFα.  631 
  632 
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Supplemental methods 633 
Fed-batch fermentation 634 
Starter cultures were grown in 10 mL of LB broth with 50 μg·mL-1 kanamycin at 25 °C and 635 
200 rpm until OD600 = 2. Starter cultures were used to inoculate a 1 L baffled shake-flask 636 
containing 200 mL of LB broth with 50 mg·L-1 kanamycin, and were grown at 25 °C and 200 637 
rpm to an OD600 between 4 and 6.  638 
A 7 L total volume (5 L working volume) bench-top fermenter (Applikon ADI 1010 Bio 639 
controller) equipped with 3 Rushton impellers and 4 baffles was used for fermentation 640 
experiments. The aeration rate was constant at 1 volume air per volume medium per minute 641 
(vvm) and the dissolved oxygen tension (DOT) was maintained above 20 % being controlled 642 
by the stirrer speed (200 - 1250 rpm). All fermentations began with an initial volume of 3 L 643 
batch salts, sterilised in the vessel by autoclaving for 20 minutes at 121 °C. Once cooled, 644 
post-autoclave additions and trace element solutions were added. Two litres of feed solution 645 
was prepared and sterilised by filtration (0.22 µm filter). For medium A (Cobra biologics), the 646 
batch salts contained: 13.3 g·L-1 K2HPO4, 4 g·L-1 (NH4)2SO4, 1.7 g·L-1 citric acid, 10 g·L-1 647 
BactoTM yeast extract and 0.16 mL·L-1 PPG 2000. The post-autoclave additions were: 1 648 
mL·L-1 trace elements solution A (comprising 5 g·L-1 citric acid, 2 g·L-1 CoCl2·6H2O, 1.2 g·L-649 
1 CuCl2·2H2O, 2.5 g·L-1 H3BO3, 2 g·L-1 Na2MoO4·2H2O, 1.2 g·L-1 MnCl2·4H2O), 10 mL·L-1 650 
trace elements solution B (comprising 6 g·L-1 FeSO4·7H2O, 0.84 g·L-1 EDTA·2H2O and  0.8 651 
g·L-1 ZnCl2), 10 g·L-1 glycerol, 1.2 g·L-1 MgSO4·7H2O, 2% (w/v) casamino acids and  1 mL·L-652 
1 50 mg · mL-1 kanamycin stock. The feed solution contained 600 g·L-1 glycerol, 5 g·L-1 653 
MgSO4·7H2O, 50 g·L-1 yeast extract, 10 g·L-1 KH2PO4, 2.1 g·L-1 K2HPO4, 2% (w/v) casamino 654 
acids, 1 mL·L-1 50 mg·mL-1 kanamycin stock and 0.5 mL·L-1 20 % arabinose stock. For 655 
medium B, casamino acids were omitted and replaced with 14 g·L-1 (NH4)2SO4 and 0.3 g·L-656 
1 of CaCl2·2H2O.  657 
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For medium C [17], the batch salts contained 14 g·L-1 (NH4)2SO4, 35 g·L-1 glycerol, 20 g·L-1 658 
BactoTM yeast extract, 2 g·L-1 KH2PO4, 16.5 g·L-1 K2HPO4, 7.5 g·L-1 citric acid, 1.5 mL · L-1 659 
concentrated H3PO4 and 0.66 mL·L-1 PPG 2000. The post-autoclave additions were 34 660 
mL·L-1 trace elements solution (comprising 3.36 g·L-1 FeSO4·7H2O, 0.84 g·L-1 ZnSO4·7H2O, 661 
0.15 g·L-1 MnSO4·H2O, 0.25 g·L-1 Na2MoO4·2H2O, 0.12 g·L-1 CuSO4·5H2O, 0.36 g·L-1 662 
H3BO3 and 48 mL·L-1 concentrated H3PO4), 10 mL·L-1 1 M MgSO4·7H2O, 2 mL·L-1 1 M 663 
CaCl2·2H2O and 1 mL·L-1 50 mg·mL-1 kanamycin stock.  The feed contained 714 g·L-1 664 
glycerol, 30 mL·L-1 1 M MgSO4·7H2O, 1 mL·L-1 50 mg·mL-1 kanamycin stock and 0.5 mL·L-665 
1 20 % arabinose stock.  666 
The pH was maintained at 6.8 by the addition of 5 M NaOH and 5 M HCl for fermentations 667 
using media A and B,  and at 7.0 by the addition of 5 M HCl or 20 % NH4OH for medium C. 668 
Polypropylene glycol (PPG) antifoam was added when required. Fed-batch fermentations 669 
were monitored using BioXpert® software (Applikon). The inoculum was added to an initial 670 
OD600 of 0.1. The fermentation was carried out at a temperature of 25 °C and the culture 671 
was induced with 0.005 % arabinose at an OD600 of 0.5. The feed solution was started 10 h 672 
after inoculation at an exponential feed rate to achieve a specific growth rate of 0.1 h-1, 673 
calculated using equation 1:  674 
𝐹 = (
1
𝑆
) × (
𝜇
𝑌𝑋𝑆
+ 𝑚) ×  𝑋0 × 𝑒
𝜇𝑡   (1) 675 
F is the feed rate in L·h-1, S is the substrate concentration in the feed in g·L-1, μ is the required 676 
specific growth rate in h-1, YXS is the yield coefficient in g biomass per g carbon source, m is 677 
the maintenance coefficient, X0 is the biomass in g and t is time. Values for YXS and m were 678 
obtained from the literature, 0.22 [19] and 0.025 [20], respectively.  679 
 680 
 681 
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SDS-PAGE 682 
4-12 % Bis-Tris NuPAGE SDS-PAGE gels (Life Technologies) were generally used to 683 
evaluate the production of recombinant proteins. Seven microliters of protein sample were 684 
mixed with 2 μL of 4x NuPAGE LDS sample buffer (Life Technologies) and 1 μL of 10x 685 
NuPAGE sample reducing agent (Life Technologies), and heated for 10 min at 70 °C. 1x 686 
electrophoresis running buffer was prepared by diluting 20x NuPAGE MES SDS running 687 
buffer (Life Technologies) in deionised water. For reducing protein electrophoresis, 0.5 mL 688 
of NuPAGE antioxidant (Life Technologies) was added to 200 mL of running buffer and used 689 
to fill the inner chamber of the electrophoresis tank. SDS-PAGE gels were run for at least 690 
45 minutes at 200 V according to the manufacturers’ protocol. Molecular size markers were 691 
used: Mark12™ Unstained Protein Standard (Life Technologies) or SeeBlue® Plus2 Pre-692 
Stained Protein Standard (Life Technologies). SDS-PAGE gels were stained using Colloidal 693 
Blue Staining (Life Technologies). SDS-PAGE gels were submerged in the fixing solution, 694 
(40 % (v/v) methanol, 10 % (v/v) glacial acetic acid) for 10 minutes, the staining solution A 695 
(20 % (v/v) methanol and 20 % (v/v) staining solution A) for 10 minutes, then staining solution 696 
B was added to a final concentration of 5 % (v/v). SDS-PAGE gels were stained for a 697 
minimum of 3 hours and de-stained with deionised water for at least 12 hours.  698 
Western blotting 699 
SDS-PAGE gels were run as above and transferred to a 0.2 μm nitrocellulose membrane 700 
(Life Technologies) using the Xcell II blot module at 30 V for 1 h (Life Technologies). Transfer 701 
buffer was prepared by the addition of 20x NuPAGE transfer buffer (Life Technologies), 10% 702 
of methanol (v/v) and 1 mL·L-1 NuPAGE antioxidant. Membranes were blocked in 5 % (w/v) 703 
skimmed milk powder (Sigma-Aldrich) in PBS for at least 1 hour. For the detection of 704 
rhTNFα, the blot was incubated with an anti-TNFα antibody (ab9635, Abcam) using 1:2500 705 
dilution in 5% (w/v) skimmed milk (Sigma-Aldrich) in PBS for 1 h, washed with 0.05% Tween-706 
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20 in PBS and successively incubated with an anti-rabbit IgG antibody conjugated with 707 
horseradish peroxidase (HRP; Sigma-Aldrich) using 1:3000 dilution for an hour. Western 708 
blots were developed using 3,3′,5,5′-tetramethylbenzidine (TMB) substrate for HRP (Sigma-709 
Aldrich).  710 
Quantification of rhTNFα from SDS-PAGE 711 
AlphaEase® software (Alpha Innotech) was used to calculate the quantity of rhTNFα as a 712 
percentage of total cell protein (TCP). Gels were photographed using an AlphaImager 713 
(Alpha Innotech) and images subjected to background subtraction using the default settings 714 
for peak-to-peak background subtraction. The percentage of soluble and insoluble 715 
recombinant protein was calculated by the software package. All samples were normalised 716 
by OD600 before loading on the SDS-PAGE gel, so each lane contained equivalent biomass.  717 
rhTNFα reference material obtained from Life Technologies was used to quantify the 718 
concentration of rhTNFα obtained at the end of each fermentation by densitometry from 719 
samples. A standard curve was generated by loading different concentrations of rhTNFα 720 
reference material on an SDS-PAGE gel. The concentration of rhTNFα from fermentation 721 
samples was quantified using a standard curve with the AlphaEase® software. The rhTNFα 722 
yields were calculated to obtain the final yield based on the final OD600 of the culture.  723 
 724 
 725 
 726 
 727 
